Hyperbaric oxygen therapy (HBOT) appears to enhance wound healing, increase bactericidal activity, and act synergistically with a number of antibiotics. The aim of this study was to evaluate the efficacy of HBOT as an adjunctive therapy in patients with hidradenitis suppurativa (HS) treated with a combination of systemic rifampicin and clindamycin. The study was a prospective, single-center, single-dose, open-label, randomized controlled clinical study of HBOT in patients with moderate to severe HS. Efficacy was measured by modified Sartorius score (SS), HS Severity Index (HSSI), Dermatology Life Quality Index (DLQI), and a visual analog scale (VAS) before treatment and after the completion of 4 and 10 weeks of treatment. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were also measured. Forty-three patients were enrolled in the study. More patients in the HBOT than in the control group showed a decrease of ≥50% from baseline parameters at week 10 for SS (100%), HSSI (100%), DLQI (95.5%), VAS (100%), ESR (100%), and CRP (72.7%). Clinically and statistically significant improvements from baseline were observed at 4 and 10 weeks in HSSI (P = 0.009 at both), SS (P = 0.021 at both), and DLQI (P = 0.044 at week 4, P = 0.009 at week 10). Adjunctive HBOT was considered to be effective in significantly improving antibiotic treatment of HS. The treatment was well tolerated, and no unexpected safety issues were identified.

No abstract

No abstract

Introduction: Hyperbaric oxygen treatment (HBOT) is one of the treatment modalities for retinal artery occlusion (RAO). HBOT may be beneficial if initiated within 2-12 hours of onset of symptoms. The objective of this study was to evaluate the usefulness of HBOT on the patients who had applied to our center for HBOT with an RAO diagnose. Methods: Sixteen patients were included in this study for a three-year period those were applied HBOT with RAO diagnosis. HBOT sessions of these patients had been started as quick as possible soon after they have arrived. Also, all patients had been started medication by ophthalmologists who sent them. To evaluate the outcome of the treatment the patients were called with telephone and ophthalmology clinic control examinations were obtained. Patients were asked survey questions about their visual ameliorations before and after HBOT. Results: Mean initiation duration of patients to get HBOT was about 28 hours. Only one patient has initiated treatment after 13 days from the event and no visual improvement was recorded. Within this patient, no visual amelioration was recorded for two more patients. Among the other 13 patients, three had 80% and more, three had 50-79% and seven had below 50% visual amelioration. Eleven of 13 patients had peripheral visual field amelioration. Discussion: With the medical treatment, an immediate intervention of HBOT was considered a useful treatment modality for RAO. The visual improvement of the visual fields was considered especially in the peripheral vision rather than central vision.

No abstract